Progressive Investment Management Corp trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,312 shares of the company's stock after selling 686 shares during the period. IDEXX Laboratories comprises 2.3% of Progressive Investment Management Corp's investment portfolio, making the stock its 20th largest position. Progressive Investment Management Corp's holdings in IDEXX Laboratories were worth $8,811,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $25,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $41,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms recently issued reports on IDXX. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price for the company. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.
View Our Latest Stock Report on IDXX
Insiders Place Their Bets
In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.
IDEXX Laboratories Stock Performance
Shares of NASDAQ IDXX traded down $1.14 during trading on Tuesday, reaching $418.81. The stock had a trading volume of 402,480 shares, compared to its average volume of 582,950. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a market cap of $33.95 billion, a PE ratio of 39.25, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The firm's 50 day moving average price is $437.08 and its two-hundred day moving average price is $442.03.
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
